{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:50:39Z","timestamp":1792457439155,"version":"4.5.0"},"reference-count":85,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. While recent EULAR recommendations have updated the standard of care for SSc, the field is rapidly evolving with novel therapeutic strategies and precision medicine approaches.<\/jats:p>\n                  <jats:p>Traditional immunosuppressive therapies\u2014including mycophenolate mofetil, cyclophosphamide and rituximab\u2014remain essential for controlling skin and lung involvement while autologous haematopoietic stem cell transplantation offers a proven disease-modifying option for selected high-risk patients. Tocilizumab and nintedanib have established roles in lung preservation in SSc-associated interstitial lung disease (SSc-ILD). In pulmonary arterial hypertension (PAH), early combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, complemented by newer agents such as selexipag and riociguat, has improved survival and quality of life. Advances in gastrointestinal, renal and musculoskeletal management continue to evolve, with promising roles for intravenous immunoglobulin and novel prokinetics.<\/jats:p>\n                  <jats:p>Crucially, emerging therapies\u2014including CD19-targeted CAR-T cells, bispecific antibodies and agents targeting interferon pathways, BAFF, melanocortin, FcRn and PDE4B\u2014reflect a shift towards personalised and biomarker-driven approaches. These innovations offer the potential to alter disease trajectory and support early, targeted intervention in SSc.<\/jats:p>\n                  <jats:p>This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains\u2014skin, ILD, PAH, scleroderma renal crisis, raynaud\u2019s phenomenon and digital ulcers, gastrointestinal and musculoskeletal involvement\u2014and emerging therapies in SSc, with an emphasis on disease-modifying approaches and future directions in personalised care.<\/jats:p>","DOI":"10.1136\/rmdopen-2025-005776","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:50:13Z","timestamp":1751410213000},"page":"e005776","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct06375005","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06655896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05925803","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05878717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04440592","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05270668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06195072","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05559580","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06375005","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06655896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05925803","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05878717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04440592","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05270668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06375005","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-9877","authenticated-orcid":false,"given":"Cristiana","family":"Sieiro Santos","sequence":"first","affiliation":[{"name":"The University of Manchester Centre for Musculoskeletal Research, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Scleroderma Programme, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025090312441880000_11.3.e005776.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"2025090312441880000_11.3.e005776.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121380"},{"key":"2025090312441880000_11.3.e005776.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2025090312441880000_11.3.e005776.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.2"},{"key":"2025090312441880000_11.3.e005776.5","doi-asserted-by":"crossref","unstructured":"Lescoat A , Eugenia B , Colic J , et al . POS1260 SYSTEMATIC LITERATURE REVIEW FOR THE 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS; Annals of the Rheumatic Diseases, 973. doi:10.1136\/annrheumdis-2023-eular.4742","DOI":"10.1136\/annrheumdis-2023-eular.4742"},{"key":"2025090312441880000_11.3.e005776.6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025090312441880000_11.3.e005776.7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2139-9"},{"key":"2025090312441880000_11.3.e005776.8","first-page":"768","article-title":"Autologous haematopoietic stem cell transplantation for systemic sclerosis: a position paper from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party","volume":"55","author":"Silva","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025090312441880000_11.3.e005776.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101469"},{"key":"2025090312441880000_11.3.e005776.10","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2025090312441880000_11.3.e005776.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.39490"},{"key":"2025090312441880000_11.3.e005776.12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0"},{"key":"2025090312441880000_11.3.e005776.13","unstructured":"Phase 2 study of rapcabtagene autoleucel (rap-cel) in adults with severe diffuse cutaneous systemic sclerosis (dcssc). 2025. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06655896"},{"key":"2025090312441880000_11.3.e005776.14","first-page":"430","article-title":"Bispecific antibodies for autoimmune and inflammatory diseases: current landscape and future directions","volume":"22","author":"Gonzalez","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025090312441880000_11.3.e005776.15","first-page":"145","article-title":"Precision medicine in systemic sclerosis: new directions for targeted therapy","volume":"20","author":"Distler","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312441880000_11.3.e005776.16","unstructured":"A study to learn about the study medicine (anifrolumab) in participants with systemic sclerosis. n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05925803"},{"key":"2025090312441880000_11.3.e005776.17","unstructured":"A study to evaluate belimumab in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD), Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05878717"},{"key":"2025090312441880000_11.3.e005776.18","unstructured":"A study to assess the efficacy and safety of mt-7117 in subjects with diffuse cutaneous systemic sclerosis. n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04440592"},{"key":"2025090312441880000_11.3.e005776.19","unstructured":"A study of tulisokibart (MK-7240) in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD), Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05270668"},{"key":"2025090312441880000_11.3.e005776.20","first-page":"454","article-title":"Design of the CONQUEST Phase 2b platform trial in systemic sclerosis-associated interstitial lung disease","volume":"83","author":"Denton","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090312441880000_11.3.e005776.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224998"},{"key":"2025090312441880000_11.3.e005776.22","unstructured":"Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis, Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06375005"},{"key":"2025090312441880000_11.3.e005776.23","doi-asserted-by":"crossref","DOI":"10.1186\/ar525","article-title":"Clinical utility of KL-6\/MUC1 in the evaluation of pulmonary fibrosis in patients with systemic sclerosis","volume":"4","author":"Kuwana","year":"2002","journal-title":"Arthritis Res Ther"},{"key":"2025090312441880000_11.3.e005776.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139009"},{"key":"2025090312441880000_11.3.e005776.25","first-page":"543","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in the Scleroderma Lung Study II","volume":"8","author":"Volkmann","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025090312441880000_11.3.e005776.26","first-page":"1034","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"73","author":"Bon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025090312441880000_11.3.e005776.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223237"},{"key":"2025090312441880000_11.3.e005776.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"2025090312441880000_11.3.e005776.29","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.130"},{"key":"2025090312441880000_11.3.e005776.30","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13573"},{"key":"2025090312441880000_11.3.e005776.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2009.12.002"},{"key":"2025090312441880000_11.3.e005776.32","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000231"},{"key":"2025090312441880000_11.3.e005776.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.4.364"},{"key":"2025090312441880000_11.3.e005776.34","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I"},{"key":"2025090312441880000_11.3.e005776.35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2025090312441880000_11.3.e005776.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"2025090312441880000_11.3.e005776.37","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7"},{"key":"2025090312441880000_11.3.e005776.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"2025090312441880000_11.3.e005776.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"2025090312441880000_11.3.e005776.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"2025090312441880000_11.3.e005776.41","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"2025090312441880000_11.3.e005776.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025090312441880000_11.3.e005776.43","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"2025090312441880000_11.3.e005776.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2025090312441880000_11.3.e005776.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2025090312441880000_11.3.e005776.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2025090312441880000_11.3.e005776.47","doi-asserted-by":"publisher","DOI":"10.5339\/gcsp.2014.26"},{"key":"2025090312441880000_11.3.e005776.48","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0969"},{"key":"2025090312441880000_11.3.e005776.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.05.004"},{"key":"2025090312441880000_11.3.e005776.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2025090312441880000_11.3.e005776.51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209087"},{"key":"2025090312441880000_11.3.e005776.52","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01898-1"},{"key":"2025090312441880000_11.3.e005776.53","first-page":"103","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"390","author":"McLaughlin","year":"2024","journal-title":"N Engl J Med"},{"key":"2025090312441880000_11.3.e005776.54","doi-asserted-by":"crossref","unstructured":"Humbert M , Kovacs G , Hoeper MM , et al . ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. ESC\/ERS Scientific Document Group 2022;3618\u2013731. doi:10.1093\/eurheartj\/ehad005","DOI":"10.1093\/eurheartj\/ehad005"},{"key":"2025090312441880000_11.3.e005776.55","article-title":"Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090312441880000_11.3.e005776.56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5258"},{"key":"2025090312441880000_11.3.e005776.57","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130658"},{"key":"2025090312441880000_11.3.e005776.58","first-page":"97","article-title":"Vascular disease in systemic sclerosis: a prospective cohort study and review of the literature","volume":"50","author":"Allanore","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312441880000_11.3.e005776.59","first-page":"910","article-title":"Targeting endothelial dysfunction in systemic sclerosis: lessons from the pulmonary arterial hypertension experience","volume":"69","author":"Distler","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312441880000_11.3.e005776.60","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm052"},{"key":"2025090312441880000_11.3.e005776.61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew216"},{"key":"2025090312441880000_11.3.e005776.62","doi-asserted-by":"publisher","DOI":"10.1177\/23971983211021747"},{"key":"2025090312441880000_11.3.e005776.63","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1340-y","article-title":"Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study","volume":"19","author":"Vigone","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312441880000_11.3.e005776.64","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13928"},{"key":"2025090312441880000_11.3.e005776.65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead093"},{"key":"2025090312441880000_11.3.e005776.66","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00334-5"},{"key":"2025090312441880000_11.3.e005776.67","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060111"},{"key":"2025090312441880000_11.3.e005776.68","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"2025090312441880000_11.3.e005776.69","doi-asserted-by":"publisher","DOI":"10.1002\/art.41933"},{"key":"2025090312441880000_11.3.e005776.70","unstructured":"Distler O , Allanore Y , Denton CP , et al . Mechanistic insights and emerging therapies in systemic sclerosis. Nat Rev Rheumatol 2019;15."},{"key":"2025090312441880000_11.3.e005776.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.04.007"},{"key":"2025090312441880000_11.3.e005776.72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09004.x"},{"key":"2025090312441880000_11.3.e005776.73","doi-asserted-by":"crossref","unstructured":"Stern EK , Carlson DA , Falmagne S , et al . Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil 2018;30. doi:10.1111\/nmo.13247","DOI":"10.1111\/nmo.13247"},{"key":"2025090312441880000_11.3.e005776.74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243651","article-title":"Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers","volume":"15","author":"Castellv\u00ed","year":"2020","journal-title":"PLoS One"},{"key":"2025090312441880000_11.3.e005776.75","first-page":"1125","article-title":"APRIL and BAFF in systemic sclerosis: correlation with disease activity and autoantibody levels","volume":"40","author":"Chen","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312441880000_11.3.e005776.76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121400"},{"key":"2025090312441880000_11.3.e005776.77","doi-asserted-by":"publisher","DOI":"10.1002\/art.22382"},{"key":"2025090312441880000_11.3.e005776.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109263"},{"key":"2025090312441880000_11.3.e005776.79","first-page":"1630","article-title":"Low-dose IL-2 therapy to modulate regulatory T cells in systemic sclerosis: emerging evidence","volume":"62","author":"Humrich","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312441880000_11.3.e005776.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102711"},{"key":"2025090312441880000_11.3.e005776.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0322-7"},{"key":"2025090312441880000_11.3.e005776.82","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00151-X"},{"key":"2025090312441880000_11.3.e005776.83","first-page":"57","article-title":"PDE4B inhibition in systemic sclerosis-associated interstitial lung disease: rationale and therapeutic implications","volume":"42","author":"Behrens","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312441880000_11.3.e005776.84","unstructured":"Humbert M , Coghlan JG , Khanna D , et al . Avenciguat (sGC stimulator) in patients with systemic sclerosis\u2013related vasculopathy: rationale and early-phase results. Eur Respir Rev 2023;32."},{"key":"2025090312441880000_11.3.e005776.85","first-page":"1123015","article-title":"Neonatal Fc receptor antagonists in autoimmune diseases: mechanisms and clinical development","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:44:31Z","timestamp":1756928671000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/rmdopen-2025-005776"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005776","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}